Notin 1mg (Varenicline Salicylate)

Adult dose

Patients should set a quit date and start taking this medicine 1 week before that date. Alternatively, they may start quitting between day 8 and day 35 after starting this medicine. Take this medicine after meals with plenty of water. The recommended dose of this medicine is as follows: after dose titration over 1 week, administer 1 mg twice daily. Days 1–3 0.5 mg once daily Days 4–7 0.5 mg twice daily Day 8 to end of treatment 1 mg twice daily Patients who cannot tolerate the adverse reactions of this medicine may temporarily or permanently reduce the dose. The treatment period is 12 weeks. For patients who successfully quit smoking with the initial 12 weeks of treatment, an additional 12 weeks of treatment with this medicine is recommended to increase the likelihood of long-term abstinence. For patients who cannot or do not wish to stop smoking abruptly, consider gradual smoking cessation while taking this medicine. Reduce smoking by 50% from the amount smoked before starting treatment within the first 4 weeks after starting this medicine, and reduce it by a further 50% within the next 4 weeks. Continue to reduce smoking so that complete cessation is achieved by 12 weeks. Administer this medicine for an additional 12 weeks for a total treatment period of 24 weeks. Encourage patients to stop smoking sooner if they feel ready. Patients who fail to quit smoking during the first 12 weeks of treatment or resume smoking after treatment should review the reasons for failure and try again. However, there are no data demonstrating the efficacy of an additional 12 weeks of treatment in patients who fail to quit smoking during the initial 12 weeks of treatment or resume smoking after treatment. No dose adjustment is necessary in patients with mild (estimated creatinine clearance > 50 ml/min and ≤ 80 ml/min) to moderate (estimated creatinine clearance ≥ 30 ml/min and ≤ 50 ml/min) renal impairment. In patients with severe renal impairment (estimated creatinine clearance < 30 ml/min), the recommended starting dose of varenicline is 0.5 mg once daily. If needed, the maximum dose is 0.5 mg twice daily. In patients with end-stage renal disease receiving hemodialysis, a maximum dose of 0.5 mg once daily may be administered if well tolerated. No dose adjustment is necessary in patients with hepatic impairment. In older patients, renal function is more likely to be reduced, so use caution when selecting the dose; monitoring renal function may be useful.

Child dose

Use is not recommended in patients under 18 years of age.

This medication is a drug that aids in smoking cessation and caution is needed as neuropsychiatric symptoms and suicidal tendencies may occur. During the intake of this medication, psychiatric symptoms such as depression, anxiety, aggression, hallucinations, and suicidal thoughts may appear; if any of these symptoms occur, the medication should be stopped immediately and a doctor should be consulted. Patients with a history of psychiatric disorders, or those who have experienced depression or suicide attempts in the past, should be observed particularly carefully. This medication is not administered to patients with hypersensitivity and pregnant or breastfeeding women should consult a doctor before use. Common side effects such as nausea, headache, insomnia, and unusual dreams may occur, but most are mild to moderate and often temporary. Patients with cardiovascular diseases may experience chest pain, myocardial infarction, and other heart-related abnormal symptoms after taking this medication; any symptoms should be reported to a doctor immediately. This medication is excreted through the kidneys, therefore dosage adjustment may be necessary for elderly patients or patients with impaired renal function. Drowsiness or dizziness may occur while driving or operating machinery, so caution is advised, and it is best to minimize or avoid alcohol consumption. Weird dreams or mood changes may occur while taking this medication; patients and caregivers should observe these changes closely. In case of overdose, standard treatment should be administered, and it should be kept out of reach of children.

• Suicidal ideation
• suicidal behavior
• suicide
• changes in behavior or thoughts
• depression
• mania
• mood swings
• psychosis
• aggressive behavior
• hallucinations

This medication should be stored in a tightly sealed container to avoid exposure to air or moisture, and the storage temperature should maintain room temperature between 1°C and 30°C. Storing it this way will help maintain the medication's effectiveness for a long time.

Appearance

Light blue, double-sided convex film-coated tablet in rectangular shape

Package unit

28 tablets/box [14 tablets/BlisterX2]